Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
67.225,60
0,22%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Atara Biotherapeutics Inc (ATRA) Atara Biotherapeutics Inc (ATRA) Notizie

ATRA

Atara Biotherapeutics (ATRA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATRA
DataOraFonteTitoloSimboloCompagnia
17/05/202403:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
10/05/202422:30Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202422:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202422:01Business WireAtara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
03/05/202422:01Business WireAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
28/03/202413:30Business WireAtara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
07/03/202400:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
29/02/202415:05Business WireAtara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T TherapyNASDAQ:ATRAAtara Biotherapeutics Inc
28/02/202422:30Business WireAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
14/02/202415:00Business WireAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus NephritisNASDAQ:ATRAAtara Biotherapeutics Inc
01/02/202408:25PR Newswire (US)Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet OncologyNASDAQ:ATRAAtara Biotherapeutics Inc
09/01/202422:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATRAAtara Biotherapeutics Inc
08/01/202415:00Business WireAtara Biotherapeutics Announces $15 Million Registered Direct OfferingNASDAQ:ATRAAtara Biotherapeutics Inc
08/01/202414:00Business WireAtara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
04/01/202422:01Business WireAtara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
03/01/202422:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATRAAtara Biotherapeutics Inc
20/12/202322:01Business WireAtara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre LaboratoriesNASDAQ:ATRAAtara Biotherapeutics Inc
11/12/202318:00Business WireAtara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual MeetingNASDAQ:ATRAAtara Biotherapeutics Inc
01/12/202322:01Business WireAtara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
30/11/202300:05Business WireAtara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023NASDAQ:ATRAAtara Biotherapeutics Inc
22/11/202322:01Business WireAtara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
17/11/202322:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ATRAAtara Biotherapeutics Inc
14/11/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATRAAtara Biotherapeutics Inc
10/11/202322:01Business WireAtara Biotherapeutics To Participate at the Stifel Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
08/11/202323:35Business WireAtara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple SclerosisNASDAQ:ATRAAtara Biotherapeutics Inc
01/11/202322:25Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATRAAtara Biotherapeutics Inc
01/11/202313:30Business WireAtara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial ResultsNASDAQ:ATRAAtara Biotherapeutics Inc
19/09/202322:50Dow Jones NewsAtara Biotherapeutics to Submit New FDA Biologics License Application in 2QNASDAQ:ATRAAtara Biotherapeutics Inc
19/09/202322:01Business WireAtara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on ComparabilityNASDAQ:ATRAAtara Biotherapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATRA

La tua Cronologia

AMEX
QMN
IQ Hedge Market Neutral ...
LSE
IALA
NASDAQ
VERV
Verve Therapeutics
USOTC
QNBC
QNB (PK)
BIT
F18332
Vontobel Financial Produ...
CSE
PDFI
Prophecy DeFi
UNSW3
ZUCKBETH
Zuck Bucks
BIT
F39138
Vontobel Financial Produ...
BIT
F06717
Vontobel Financial Produ...
EU
S554S
S554S
COIN
NRGETH
Energi
LSE
PHPT
Wt Physi Platin
LSE
PGX
Punch Graphix
DGFX
BSHINJAUSDT
Shibnobi
KOSPI
007540
Sempio
TSXV
AEMC
Alaska Energy Metals
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network